These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19519348)

  • 1. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction.
    Almond LM; Yang J; Jamei M; Tucker GT; Rostami-Hodjegan A
    Curr Drug Metab; 2009 May; 10(4):420-32. PubMed ID: 19519348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions.
    Yang J; Liao M; Shou M; Jamei M; Yeo KR; Tucker GT; Rostami-Hodjegan A
    Curr Drug Metab; 2008 Jun; 9(5):384-94. PubMed ID: 18537575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of HepaRG and human hepatocyte data in predicting CYP induction drug-drug interactions via static equation and dynamic mechanistic modelling approaches.
    Grime K; Ferguson DD; Riley RJ
    Curr Drug Metab; 2010 Dec; 11(10):870-85. PubMed ID: 21208171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information.
    Hisaka A; Ohno Y; Yamamoto T; Suzuki H
    Pharmacol Ther; 2010 Feb; 125(2):230-48. PubMed ID: 19951720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance.
    Iga K
    J Pharm Sci; 2016 Mar; 105(3):1307-17. PubMed ID: 26886336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
    Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
    Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interindividual variability in inhibition and induction of cytochrome P450 enzymes.
    Lin JH; Lu AY
    Annu Rev Pharmacol Toxicol; 2001; 41():535-67. PubMed ID: 11264468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
    Foti RS; Wahlstrom JL
    IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
    Brown HS; Galetin A; Hallifax D; Houston JB
    Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment.
    Polasek TM; Lin FP; Miners JO; Doogue MP
    Br J Clin Pharmacol; 2011 May; 71(5):727-36. PubMed ID: 21223357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of cytochrome p450 induction: potential for drug-drug interactions.
    Jana S; Paliwal J
    Curr Protein Pept Sci; 2007 Dec; 8(6):619-28. PubMed ID: 18220847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.
    VandenBrink BM; Isoherranen N
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):66-77. PubMed ID: 20047147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.
    Riley RJ; Wilson CE
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):557-72. PubMed ID: 25659570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction.
    Matoulková P; Pávek P; Malý J; Vlček J
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):425-35. PubMed ID: 24451000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition and induction of cytochrome P450 and the clinical implications.
    Lin JH; Lu AY
    Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of cytochrome P450 enzymes: a view on human in vivo findings.
    Hukkanen J
    Expert Rev Clin Pharmacol; 2012 Sep; 5(5):569-85. PubMed ID: 23121279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dealing with the complex drug-drug interactions: towards mechanistic models.
    Varma MV; Pang KS; Isoherranen N; Zhao P
    Biopharm Drug Dispos; 2015 Mar; 36(2):71-92. PubMed ID: 25545151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concept: The Use of Targeted Immunoaffinity Proteomics for Routine Assessment of In Vitro Enzyme Induction.
    MacLean C; Weiß F; Poetz O; Ebner T
    J Pharm Sci; 2017 Dec; 106(12):3453-3457. PubMed ID: 28778426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction.
    Shou M; Hayashi M; Pan Y; Xu Y; Morrissey K; Xu L; Skiles GL
    Drug Metab Dispos; 2008 Nov; 36(11):2355-70. PubMed ID: 18669588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive-Unlabeled Learning for inferring drug interactions based on heterogeneous attributes.
    Hameed PN; Verspoor K; Kusljic S; Halgamuge S
    BMC Bioinformatics; 2017 Mar; 18(1):140. PubMed ID: 28249566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.